Immune Disease Institute

Cells: The New Drug

The Center for Human Cell Therapy (CHCT), funded by a $12.65 million grant from the National Institutes of Health, is now up and running at the CBR Institute's facility at 800 Huntington Ave in Boston. The Center seeks major advancements in an exciting new field of medicine. This image shows mesenchymal stem cells, isolated from amniotic fluid, that are part of a CHCT project to heal defective diaphragms in infants. more >>

Rao Lab Finds Key to T Cell's Shifting Proteome When immune T cells encounter the enemy-a virus, bacteria or other foreign invader-they transform from a state of quiet readiness to fully armed fighters. This process of T cell activation, which occurs in a day or less, requires the cell to produce a host of new proteins to fill its arsenal. more >>
IDI and GlaxoSmithKline Kick Off Research Alliance The Immune Disease Institute and GlaxoSmithKline (GSK) are gearing up to launch their five-year, $25 million research collaboration, aimed at speeding the development of new medicines to fight autoimmune and inflammatory disease. more >>
Immune Cells Kill Foes By Disrupting Mitochondria Two Ways "This work gives us a new understanding of a major T cell defense pathway," Lieberman says. The results appeared in the May 16th issue of Cell. more >>
© 2004 The Immune Disease Institute All rights reserved. 800 Huntington Avenue, Boston, Massachusetts, 02115

CBRI has, in order to reflect its principal research programs, taken the new name of Immune Disease Institute. To celebrate this important milestone in our history, we are creating a new web site. We look forward to sharing it with you in the fall.